$
SBFM
News: Sunshine Biopharma Receives Second Tranche From Previously Announced $2,000,000 And Financing for Coronavirus Treatment
Mon, October 26, 2020, 8:00 AM EDT
MONTREAL, QC / ACCESSWIRE / October 26, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the second tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $550,000 that the Company has received under this financing. The proceeds will be used for the ongoing development of the Company's Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company's flagship anticancer compound targeted for pancreatic cancer.
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.1 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients.
"We are excited about the financing arrangement we have in place with RB Capital as it provides with the funding required for our research projects," said Camille Sebaaly, Chief Financial Officer of Sunshine Biopharma.
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Story continues
Advertisement
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting.
Newsfile
Holiday Island Holdings, Inc. Enters the Under Contract Phase to Acquire a High Yield RV Park Located near the Dallas / Fort Worth Metro for $1.300,000
Newsfile Corp.
Mon, October 26, 2020, 8:00 AM EDT
Holiday Island, Arkansas--(Newsfile Corp. - October 26, 2020) - Holiday Island Holdings, Inc. (OTC PINK: HIHI) - operating in the recreational and remote living real estate market - released the news today that it is planning to enter into a joint venture arrangement to acquire and operate an existing RV park near the Dallas/Ft. Worth MetroPlex. The acquisition price for the park is $1.3 million.
The preliminary agreement calls for HIHI to lease and manage the property from the joint venture partner and retain all revenues and profit. Currently the property is generating approximately $90,000 in annual EBITDA. The park and its amenities can, and are planned to be enhanced and expanded, and the profits thereby improved.
Texas is the home to 49 Fortune 500 companies including Exxon Mobile, AT & T, Sysco, American Airlines, Toyota, BAE Systems, Siemens, Shell Oil Company, and 2.4 million small businesses, according to the Texas Economic Development Corporation. Major companies such as Tesla, Charles Swab and many others continue to grow, and they are moving to Texas, making this a hot spot for real estate investments, and bringing value to shareholders.
Gene Thompson - CEO and Chief Strategist of Holiday Island Holdings said, "We are excited about reaching this phase on this park with the expectation of closing in mid-December."
He further stated: "Our primary focus is to locate opportunities that are now operating in an earnings mode, which may be underperforming, and therefore undervalued. Our management team is experienced in locating, acquiring, enhancing, and remediating these situations, and they expect to increase their profitability accordingly. While we are seeking existing operational properties, we will also consider those that have physical facilities in place, but are not currently operational, and in fact, we are sharply focused on two of those prospects at this time. We will keep you apprised of our progress."
We are also seeking suitable funding to become a significant player in our chosen geographic real estate segments. We are currently evaluating numerous prospective recreational and remote-living opportunities, and we will report these to shareholders and the investment community as they materialize.
Holiday Island Holdings, Inc. will keep both its shareholders and public completely informed of the entire process as the details continue to develop. Please watch for press releases about the Company's progress. For additional information, please visit the Company's website at www.holidayislandholdings.com.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.
HIHI Contact:
Gene Thompson, CEO & Chairman
Phone: (479) 244-6047
Email: sgthompson@holidayislandholdings.com
Website: www.holidayislandholdings.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66829
Mon, October 26, 2020, 8:00 AM EDT
MONTREAL, QC / ACCESSWIRE / October 26, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the second tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $550,000 that the Company has received under this financing. The proceeds will be used for the ongoing development of the Company's Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company's flagship anticancer compound targeted for pancreatic cancer.
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.1 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients.
"We are excited about the financing arrangement we have in place with RB Capital as it provides with the funding required for our research projects," said Camille Sebaaly, Chief Financial Officer of Sunshine Biopharma.
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Story continues
Advertisement
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting.
Newsfile
Holiday Island Holdings, Inc. Enters the Under Contract Phase to Acquire a High Yield RV Park Located near the Dallas / Fort Worth Metro for $1.300,000
Newsfile Corp.
Mon, October 26, 2020, 8:00 AM EDT
Holiday Island, Arkansas--(Newsfile Corp. - October 26, 2020) - Holiday Island Holdings, Inc. (OTC PINK: HIHI) - operating in the recreational and remote living real estate market - released the news today that it is planning to enter into a joint venture arrangement to acquire and operate an existing RV park near the Dallas/Ft. Worth MetroPlex. The acquisition price for the park is $1.3 million.
The preliminary agreement calls for HIHI to lease and manage the property from the joint venture partner and retain all revenues and profit. Currently the property is generating approximately $90,000 in annual EBITDA. The park and its amenities can, and are planned to be enhanced and expanded, and the profits thereby improved.
Texas is the home to 49 Fortune 500 companies including Exxon Mobile, AT & T, Sysco, American Airlines, Toyota, BAE Systems, Siemens, Shell Oil Company, and 2.4 million small businesses, according to the Texas Economic Development Corporation. Major companies such as Tesla, Charles Swab and many others continue to grow, and they are moving to Texas, making this a hot spot for real estate investments, and bringing value to shareholders.
Gene Thompson - CEO and Chief Strategist of Holiday Island Holdings said, "We are excited about reaching this phase on this park with the expectation of closing in mid-December."
He further stated: "Our primary focus is to locate opportunities that are now operating in an earnings mode, which may be underperforming, and therefore undervalued. Our management team is experienced in locating, acquiring, enhancing, and remediating these situations, and they expect to increase their profitability accordingly. While we are seeking existing operational properties, we will also consider those that have physical facilities in place, but are not currently operational, and in fact, we are sharply focused on two of those prospects at this time. We will keep you apprised of our progress."
We are also seeking suitable funding to become a significant player in our chosen geographic real estate segments. We are currently evaluating numerous prospective recreational and remote-living opportunities, and we will report these to shareholders and the investment community as they materialize.
Holiday Island Holdings, Inc. will keep both its shareholders and public completely informed of the entire process as the details continue to develop. Please watch for press releases about the Company's progress. For additional information, please visit the Company's website at www.holidayislandholdings.com.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.
HIHI Contact:
Gene Thompson, CEO & Chairman
Phone: (479) 244-6047
Email: sgthompson@holidayislandholdings.com
Website: www.holidayislandholdings.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66829
